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Abstract
Background: Hypertension (HT) affects an estimated one billion people worldwide, nearly three-quarters of whom live in
low- or middle-income countries (LMICs). In both developed and developing countries, only a minority of individuals with
HT are adequately treated. The reasons are many but, as with other chronic diseases, they include weaknesses in health
systems. We conducted a systematic review of the influence of national or regional health systems on HT awareness,
treatment, and control.
Methods and Findings: Eligible studies were those that analyzed the impact of health systems arrangements at the regional
or national level on HT awareness, treatment, control, or antihypertensive medication adherence. The following databases
were searched on 13th May 2013: Medline, Embase, Global Health, LILACS, Africa-Wide Information, IMSEAR, IMEMR, and
WPRIM. There were no date or language restrictions. Two authors independently assessed papers for inclusion, extracted
data, and assessed risk of bias. A narrative synthesis of the findings was conducted. Meta-analysis was not conducted due to
substantial methodological heterogeneity in included studies. 53 studies were included, 11 of which were carried out in
LMICs. Most studies evaluated health system financing and only four evaluated the effect of either human, physical, social,
or intellectual resources on HT outcomes. Reduced medication co-payments were associated with improved HT control and
treatment adherence, mainly evaluated in US settings. On balance, health insurance coverage was associated with improved
outcomes of HT care in US settings. Having a routine place of care or physician was associated with improved HT care.
Conclusions: This review supports the minimization of medication co-payments in health insurance plans, and although
studies were largely conducted in the US, the principle is likely to apply more generally. Studies that identify and analyze
complexities and links between health systems arrangements and their effects on HT management are required, particularly
in LMICs.
Please see later in the article for the Editors’ Summary.
Citation: Maimaris W, Paty J, Perel P, Legido-Quigley H, Balabanova D, et al. (2013) The Influence of Health Systems on Hypertension Awareness, Treatment, and
Control: A Systematic Literature Review. PLoS Med 10(7): e1001490. doi:10.1371/journal.pmed.1001490
Academic Editor: Mark J. Caulfield, Barts and The London School of Medicine and Dentistry, United Kingdom
Received February 22, 2013; Accepted June 19, 2013; Published July 30, 2013
Copyright:  2013 Maimaris et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was part of the HOPE-4 project. This part of the HOPE-4 project was funded by the Canadian Institutes of Health Research with an award
number IHR-120389. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: BP, blood pressure; HT, hypertension; LMIC, low- and middle-income country; mmHg, millimeters of mercury; OR, odds ratio; RCT, randomized
controlled trial; RR, relative risk.
* E-mail: willmaimaris@yahoo.com
PLOS Medicine | www.plosmedicine.org 1 July 2013 | Volume 10 | Issue 7 | e1001490
Introduction
Hypertension (HT) is common worldwide, affecting an
estimated billion people, nearly three-quarters of whom live in
low or middle income countries (LMICs) [1]. HT is second, after
smoking, as a contributor to the Global Burden of Disease in the
latest (2010) analysis [2]. In most individuals it is easily treated and
controlled, with effective control reducing deaths and disability
from a number of conditions, including cerebrovascular, cardio-
vascular, and renal disease [3]. Yet in both developed and
developing countries, a significant proportion of people with HT
remain unaware of their diagnosis, and of those who are aware,
only a minority are treated and have their HT successfully
controlled [4]. The reasons are many but, as with other chronic
diseases, they include weaknesses in health systems, related to both
structures and ways in which systems function [5,6]. Health
systems have been defined by the World Health Organization as
‘‘all the organizations, institutions and resources that are devoted
to producing health actions’’ [7] and weaknesses may exist at the
national, regional, district, community, and household level.
Previous systematic reviews have examined the effects of health
systems interventions delivered at the community or health facility
level on HT care, such as educational interventions that target
providers, organisational interventions strengthening collaboration
between physicians and pharmacists, and using electronic records
to improve management [8–10]. However, we are unaware of any
previous systematic review exploring the effect of actions
originating at national or regional health systems level, including
health policies, programs, and interventions, on HT outcomes.
Actions that have been hypothesized to influence HT care include
strategies for procurement of essential medications, the existence
of simple national guidelines for HT management, introduction of
financial incentives for health care practitioners to diagnose or
treat HT, and enhanced health insurance coverage [1]. To address
this gap, we systematically reviewed the literature examining the
effect of national or regional health system arrangements on HT
care and control, and make recommendations for future research
and policy.
Methods
A protocol for this study has been published on the
PROSPERO international prospective register of systematic
reviews, with the record number PROSPERO 2012:CRD42
012002864 [11]. We used an established framework to illustrate
the health system and its elements and guide our systematic
review (Figure 1). This conceptual framework, which has been
found useful in understanding the systems failings that impede
effective management of non-communicable diseases [12,13],
consists of four domains relating to key system level inputs that
are required for effective chronic disease care: namely, physical
resources (e.g., health facilities and diagnostic equipment), human
resources (e.g., trained health care workers and managers),
intellectual resources (e.g., treatment guidelines), and social
resources (which draws on the concept of social capital and
includes organizational measures to enhance collaboration). The
existence of inputs is insufficient in itself, without effective systems
to finance, deliver, and govern care; and these are also reflected
in the framework. All of these domains influence the impact of
the health system inputs on the health care outcomes of interest,
which are HT awareness, treatment, control, and antihyperten-
sive medication adherence in this case. The framework aims to
capture the complex interactions and inter-relationships that exist
between the elements within a health system, acknowledging that
success of health systems does not simply require a ‘‘laundry list’’
of building blocks (as the WHO’s 2007 framework is often
perceived), but requires effective integration and alignment of
these inputs [14,15]. The framework also highlights the
important role that context plays in shaping the relationship
between health systems inputs and outcomes, recognizing the
complex adaptive nature of health systems so that changes may
yield different results in different settings [16].
Inclusion Criteria
We included studies that reported on the effects of national or
regional health system level arrangements (factors, interventions,
policies, or programs) on HT control and key upstream
Figure 1. Schematic diagram of health systems conceptual framework.
doi:10.1371/journal.pmed.1001490.g001
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determinants of control: HT awareness, treatment, and medica-
tion adherence. Definitions of these outcomes are given in Box 1.
We included studies looking at any adult population, including
general populations, populations on treatment, and studies of
people with specific co-morbidities, such as diabetes.
The following types of studies were included: (1) Studies, such as
controlled trials, cohort studies, and cross-sectional studies, which
quantify the effects on HT outcomes of interventions, policies, or
programmes, which are enacted at national or regional health
system level, acting on one or more domains of the health-system.
(2) Studies, such as qualitative studies, which report on the views
and experiences of actors (e.g., patients, physicians, or policy
makers) on national or regional health-system level barriers to HT
awareness, treatment, control, or antihypertensive medication
adherence. (3) Studies reporting on the impact of national or
regional HT care policies or interventions that have relevance for
other disease programs or for the design of the health system more
broadly, such as those that require or lead to changes in primary
care provision or other general aspects of the health system.
Quantitative studies were included only if they reported a
measure of association between the health system arrangement
under investigation and at least one of the HT outcomes of interest
(Box 1).
There were no date or language restrictions.
Studies that evaluated interventions, policies, or programs that
are enacted at the individual level (e.g., provider or patient level)
or organizational level of the health system (e.g., hospital or
primary care organization), and do not require change at the level
of the national or regional health system were excluded.
Search Strategy
The search strategy and terms were developed collaboratively
with an information specialist. Key words (MeSH terms) and free
text terms were identified for each domain of our health systems
framework and combined with search terms for HT outcomes to
generate the search strategy for the electronic databases Medline,
Embase, and Global Health (Text S2). To improve the likelihood
of identifying studies from LMICs, modified searches were
performed on the following databases: Latin American and
Caribbean Health Sciences Literature (LILACS), Africa-Wide
Information, Index Medicus for the South-East Asian Region
(IMSEAR), Index Medicus for the Eastern Mediterranean Region
(IMEMR) Western Pacific Rim Region Index Medicus (WPRIM).
All databases were searched from inception to the present day on
8th May 2013. To identify further relevant studies, reference lists
of included articles were hand searched and a forward citation
search was performed on included studies using Web of Science.
Study Selection
Two reviewers independently screened the search results by title
and abstract for potential eligibility. Full texts of potentially
suitable articles were obtained and were further screened for
inclusion by two reviewers. Disagreements in the screening of full
texts were resolved by a third reviewer with expertise in health
systems and this was required for four of the 122 screened papers.
Data Extraction for Study Setting, Methodology, and
Findings
A data extraction form was developed in Microsoft Excel. Data
were extracted from each study on study design, setting, health
system domains investigated, study methods, and outcomes (Table
S1). Where multiple analytical models were used for HT outcomes
in a study, data were taken from the analytical model that had the
highest level of control for other confounding factors. Data
extraction was performed independently by two reviewers and
compared and checked for disparities. Erroneous or inconsistent
data were identified in one of the included papers, and we
attempted to contact the authors of this paper for clarification.
Clarification of these data was not forthcoming, so these data were
excluded from the analysis.
Risk of Bias Assessment
Included studies were independently assessed for risk of bias by
two reviewers. For observational study designs, risk of bias was
assessed using a simple proforma for three domains: selection bias,
information bias (differential misclassification and non-differential
misclassification), and confounding (Text S3). Assessment of non-
differential misclassification took into consideration the reliability
of the measure used to report HT outcomes, which was
particularly important for medication adherence, where a variety
of methods were used for measurement. Risk of bias for each
domain was assessed as either low, unclear, or high. Studies that
had a low risk of bias in each domain, including a low risk of
confounding, were classified as having a low overall risk of bias.
For randomized studies the Cochrane risk of bias tool was used
[17]. Qualitative studies were evaluated for quality using an
adapted version of a checklist used in a previous series of mixed
methods systematic reviews incorporating both quantitative and
qualitative studies (Text S4) [18,19].
Assessment of Context and Complexity Considerations
Due to the recognized importance of context and complexity to
health systems research [20], we examined the extent to which
included studies describe and explore these factors. We assessed to
what extent studies had described the sociodemographic, political,
or economic context in which they were conducted and the wider
health system setting. We also assessed whether studies demon-
strated a consideration of the complexity of health systems, includ-
ing addressing inter-relationships between different health systems
domains, for example, those between financing arrangements and
retention of skilled health care workers, as well as interactions with
contextual factors, such as the level of poverty or literacy amongst
the population being served. This process was performed by one
reviewer and checked for consistency by a second reviewer.
Data Synthesis and Analysis
A narrative synthesis was performed, with studies categorized
according to the health system domain they investigated and the
Box 1. Definitions of Included Hypertension
Outcomes
(1) HT awareness. Defined as persons with clinically
measured HT who have been diagnosed by a health care
professional as hypertensive.
(2) HT treatment. Defined as the use of at least one
antihypertensive medication in an individual with known
HT.
(3) Antihypertensive medication adherence. Defined as
consistently taking the antihypertensive medication regi-
men as prescribed by the health care provider.
(4) HT control: defined as the achievement of BP below
140/90 mmHg (or other explicitly defined threshold) in
individuals being treated for HT, or, alternatively, mea-
sured by the mean BP amongst individuals with HT.
Influence of Health Systems on Hypertension Care
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setting in which the study was performed. For making causal
inferences about reported associations between health systems
arrangements and HT outcomes, randomized controlled trials
(RCTs) were considered the strongest study design, followed by
cohort studies and then case-control studies. Cross-sectional
studies and ecological studies, alone, were not considered
appropriate for causal inference. Meta-analysis was not conducted
as we judged that the included studies were heterogeneous in
important aspects, including: populations (different ages and
settings), study designs (cross-sectional, case-control, cohort),
variable definitions (including different definitions of exposures
and outcomes), comparisons (e.g., different type of insurance
schemes), and analytical strategies (adjustment for different
confounders).
Results
The screening process is described using an adapted Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flowchart (Figure 2) [21]. 5,514 articles were screened
by title and abstract for inclusion. The full text of 122 of the 5,514
articles was obtained and assessed for eligibility. 53 studies met
eligibility criteria for this review. Full details of the included
studies, including study design, setting, key findings, and risk of
bias assessment can be found in Table S1. 51 of the included
studies were quantitative and two were qualitative [22,23]. Of the
51 quantitative studies, one was a RCT [24]; 12 were cohort
studies [25–34], two of which were retrospective [30,34]; three
were case-control studies [35–37]; 32 were cross-sectional studies;
and three were ecological studies [38–40]. 42 of the 53 studies
(79%) were carried out in countries classified by the World Bank
as high-income countries, 36 of which were in the US. Six studies
were carried out in upper middle-income countries [38,41–45],
three in lower middle-income countries [23,28,46], and one in a
low-income country [47]. Table 1 describes the health systems
factors investigated, classified into the domains of the conceptual
framework (Figure 1).
Effect of Health System Arrangements on Hypertension
Outcomes
Physical resources. One study examined the effect of health
system factors relating to physical resources (Table 2). This study
was conducted in a low-income country, Ethiopia, and examined
the effect of distance that patients were required to travel to health
facilities providing HT care [47]. The study was cross-sectional in
design and had a low risk of bias for all methodological domains
assessed. The study reported a moderate positive association
between a shorter distance of travel to a health facility and
antihypertensive medication adherence (odds ratio [OR] for
medication adherence in those with a travel time to health
facilities of less than 30 min versus travel time of more than
30 min, 2.02, 95% CI 1.19–3.43).
Human resources. Three studies examined the effect of
health system factors relating to human resources, none of which
had a low risk of bias (Table 2). Two of the three were conducted
in an upper-middle income country (both in Mexico), and one was
conducted in a high-income country (US).
One US cross-sectional study evaluated the effect of the treating
physician’s seniority on HT control [48]. This study found a small
positive association between seniority of treating physician and
HT control. The adjusted OR for HT control was 1.23 (95% CI
1.08–1.39) for patients treated by an attending level physician
compared to those treated by a resident level physician.
One Mexican cross-sectional study evaluated the impact of
being treated by a specialist on HT control [43]. This study found
a moderately increased risk of uncontrolled HT in hypertensive
individuals treated by non-specialist physicians (general practi-
tioners) compared to those treated by specialists (adjusted OR
1.43, 95% CI 1.20–1.71).
Another Mexican cross-sectional study evaluated the effect of
the density of health professionals and did not find an association
with HT treatment or control [41].
Intellectual resources. None of the included studies evalu-
ated the effects of health system factors relating to intellectual
resources on HT outcomes.
Social resources. None of the included studies evaluated the
effects of health system factors relating to social resources.
Health Systems Financing. 38 quantitative studies analyzed
the effects of health systems financing on HT outcomes (34 of these
studies were conducted in high-income countries and four in
middle-income countries). Four different health system arrange-
ments were analyzed, with 21 studies assessing effects of health
insurance coverage, 11 examining the effects of medication co-
payments or costs, three analyzing co-payments for medical care,
and two looking at physician remuneration models.
Twenty of 21 studies evaluating health insurance coverage were
conducted in the US and one in Mexico (Table 3). Seven of the 21
studies had a low risk of bias. Two were cohort studies, three were
case-control studies, and 16 were cross-sectional studies. 19 of the
21 studies evaluating health insurance reported direct comparisons
of HT outcomes in insured and uninsured patients, while two
studies only compared private and public insurance schemes. Two
cohort studies, both set in the US, compared uninsured patients
with insured patients [26,49]. One of the cohort studies had a 9-y
follow-up and found that being uninsured was associated with an
increased risk of both unawareness of HT (relative risk [RR] of
unawareness in uninsured versus insured patients 1.12, 95% CI
1.00–1.25) and inadequate control of HT (RR of inadequate
control in uninsured versus insured patients 1.23, 95% CI 1.08–
1.39) [49]. The other cohort study had a follow up period of
30 mo and found that medication adherence was lower in
uninsured patients compared to insured patients (OR for
medication adherence for uninsured versus insured 0.426, 95%
CI 0.282–0.757) [26]. One of two US set case-control studies
comparing HT outcomes in uninsured and insured patients
reported that insurance was associated with an increased
likelihood of HT control (OR for HT control in insured versus
uninsured 2.15, 95% CI 1.02–4.52) [36]. The other case-control
study reported a non-significant association between being
uninsured and having severe uncontrolled HT (OR for severe
uncontrolled HT in uninsured versus insured 1.9, 95% CI 0.8–
4.6). [35]. Fifteen cross-sectional studies reported comparisons of
HT outcomes in insured and uninsured patients. Eight of these 15
studies reported that insurance was associated with improved HT
treatment, control or medication adherence [41,50–56]. The
seven other cross-sectional studies that compared HT outcomes in
insured patients and uninsured patients, reported no significant
negative or positive associations between insurance status and HT
outcomes [57–63]. Two further studies looking at health insurance
status compared HT outcomes in patients with public and private
health insurance. A case-control study set in the US found
increased odds of HT control in patients with private insurance
compared to patients with public insurance (OR for HT control
3.40, 95% CI 1.25–9,28) [37]. A cross-sectional study, also set in
the US, found no significant association between private or public
insurance and HT awareness or treatment, but did report
significantly lower levels of systolic blood pressure (BP) in patients
Influence of Health Systems on Hypertension Care
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with private insurance compared to public insurance (p,0.05)
[64].
Fourteen quantitative studies measured the association of
medication co-payments or costs with HT control or treatment
adherence, nine of which were set in the US, and one in each of
Cameroon, China, Finland, Israel, and Brazil (Table 4). Two of
the 14 studies had a low risk of bias. Seven of the 14 studies
were cohort studies, one was a case-control study, and six were
cross-sectional studies. All seven cohort studies reported associa-
tions between increased medication costs or co-payments and
reductions in HT control or reduced adherence to antihyperten-
sive medication [25,27,29,30,32,34,65], although for one of these
seven cohort studies, the association between increased co-
payments and reduced medication adherence was only found for
low medication co-payments, and at high co-payment levels
medication adherence was actually found to increase (OR for
Figure 2. PRISMA flowchart.
doi:10.1371/journal.pmed.1001490.g002
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medication adherence versus baseline of 1 for US$0 co-payments
was 0.72 for US$1–US$9 co-payments (p,0.05), 1.02 for US$10–
US$29 co-payments (p.0.05), and 1.32 for co-payments .US$30
(p,0.05)) [34]. Five cross-sectional studies and one case-control
study also examined associations between medication co-payments
or costs and HT control or adherence to antihypertensive
medication [42,45,66–68]. All six of these studies reported
significant associations between reduced co-payments or costs
and improved HT control or medication adherence. One of these
cross-sectional studies, set in China, also looked at the effect of
medication costs on HT treatment rates. This study found that
0.0% of people given access to free antihypertensive medication
remained untreated compared to 14.7% who had to pay for
medication (p,0.001) [45]. One cross-sectional study set in
Cameroon examined the association of medication costs with
HT awareness and did not find one, although the confidence inter-
vals were wide (OR for HT awareness for high medication cost
versus low medication cost 0.44, 95% CI 0.07–2.75) [46]. Two
qualitative studies, one from the US and one from Nigeria, cited
cost of medications as a barrier to medication adherence [22,23].
Three studies assessed co-payments or costs of medical care (not
simply medications), two of which were conducted in the US
(an RCT and a case-control study) and one in Hong Kong
(a cohort study). (Table 4) [24,33,36]. One of the three studies,
the cohort study from Hong-Kong, had a low risk of bias [33].
The RCT reported a higher mean BP level amongst individuals
with HT who had cost-sharing insurance plans compared to
those with free care, although this was non-significant for systolic
BP [24]. The adjusted mean difference in diastolic BP between
the two groups was 1.9 mm mercury (mmHg) (95% CI 0.3–
3.5 mmHg) and the adjusted mean difference in systolic BP
was 1.8 mmHg (95% CI 20.6 to 4.5 mmHg). The case-control
study reported that cost of care was a deterrent to BP control
(adjusted OR for BP control when cost not a deterrent versus
cost as a deterrent: 2.35, 95% CI 1.19–4.67) [36]. The cohort
study, which was set in Hong Kong, found, conversely, that
being a fee payer was associated with improved adherence to
prescribed antihypertensive medications compared to fee waivers
(adjusted OR for adherence fee payers versus fee waivers 1.14,
95% CI 1.09–1.19) [33].
Two studies evaluated the association of physician remunera-
tion models with HT control or treatment adherence, one an
ecological study set in Canada, and one a US cross-sectional study
(Table 5). Neither study had a low risk of bias. The US study
Table 1. Health system arrangements investigated by included quantitative studies, classified by health system domain.
Health System Framework
Domaina
Health System Factor Being
Investigated
Number of
Studies
Number of Studies and
Study Designs Setting of Studies (Countries)
Physical resources Distance to health facilities 1 Cross-sectional (1) Ethiopia (1)
All physical resources studies 1 Cross-sectional (1) Ethiopia (1)
Human resources Level of training/specialism of
treating physician
2 Cross-sectional (2) US (1), Mexico (1)
Supply of health professionals 2 Cross-sectional (1) Mexico (1)
All human resources studies 3 Cross-sectional (3) US (1), Mexico (2)
Intellectual resources All intellectual resources studies 0 0 studies n/a
Social resources All social resources studies 0 0 studies n/a
Health system financing Health insurance status 21 Cohort (2)
Case-control (3)
Cross-sectional (16)
US (20), Mexico (1)
Medication costs or medication
co-payments
14 Cohort (7)
Case-control (1)
Cross-sectional (6)
US (9), Finland (1), Brazil (1), Israel (1), China (1),
Cameroon (1)
Co-payments for medical care 3 RCT (1)
Cohort (1)
Case-control (1)
US (2), Hong-Kong (1)
Physician remuneration model 2 Cross-sectional (1)
Ecological (1)
US (1), Canada (1)
All financing studies 38 1 RCT (1)
Cohort (10)
Case-control (3)
Cross-sectional (23)
Ecological (1)
US (30), Canada (1), Mexico (1), Hong-Kong (1),
Israel (1), Finland (1), Brazil (1), China (1),
Cameroon (1)
Governance and delivery Care delivered by private or public
provider
3 Cross-sectional (3) US (1), Greece (1), South Africa (1)
Routine place of care 6 Cross-sectional (6) US (6)
Routine treating physician 7 Case-control (1)
Cross-sectional (6)
US (7)
Either a routine physician or place
of care
1 Case-control (1) US
All governance and delivery studies 16 Case-control (2)
Cross-sectional (14)
US (14), Greece (1), South Africa (1)
aSome studies separately assess more than one health system arrangement.
doi:10.1371/journal.pmed.1001490.t001
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reported improved rates of HT control amongst patients treated
under a capitation model compared to fee-for service patients
(adjusted OR for HT control 1.82, 95% CI 1.02–3.27 for
capitation versus fee-for-service patients) [69]. The Canadian
study reported highest rates of HT treatment and control among
practices using a capitation model, compared to fee-for-service
and salary models [40]. HT awareness levels were highest in
practices with a fixed salary remuneration model.
Delivery and Governance. 16 studies examined the effects
of health systems arrangements relating to delivery and gover-
nance on HT outcomes (Table 6). Fifteen of these studies were
conducted in high-income countries and one in a LMIC. Four
different health systems arrangements were analyzed, with six
studies evaluating having a routine place of care for HT
management, seven studies evaluating having a routine physician
for HT care, one study evaluating having either a routine place or
physician for HT care, and four studies assessing whether care was
delivered by the private versus the public sector.
All six studies analyzing having a routine place of care for HT
were conducted in the US, and all were cross sectional in design,
with five of the six having a low risk of bias. Five of these six studies
reported a significant association between a routine place of care
and improved HT awareness, treatment, or control [53,55,56,70,71].
One study found no association between a routine place of care and HT
awareness or control [58]. No studies analyzed medication adherence.
Of the seven studies assessing the effects of having a routine
physician for HT care, all were conducted in the US. Two of the
seven studies had a low risk of bias. One was a case-control study
and six were cross-sectional studies. The case-control study and
five of the six cross-sectional studies found that having routine care
from the same physician was significantly associated with an
improvement in HT awareness, treatment control, or medication
adherence [35,53,55,57,60,72,73]. One study did not find a signi-
ficant association between a routine physician and HT control [57].
A single case-control study, which did not have a low risk of
bias, analyzed having either a routine place of care or physician for
HT care in the US [36]. It found that having either was strongly
associated with improved HT control, with some imprecision in
the effect estimate (adjusted OR for HT control 7.93, 95% CI 3.86–
16.29 for a regular source of care versus no regular source of care).
Four studies assessed private versus public provision of care,
with one set in each of South Africa, US, Brazil, and Greece. All
four studies conducted were of cross-sectional design and none
had a low overall risk of bias. One study set in Brazil found that
non-adherence to antihypertensive medication was more likely in
patients treated in the public versus private sector (OR for non-
adherence in patients treated by public health service versus
private medical provider 1.8, 95% CI 1.1–2.7) [42]. One study,
set in the US, found no significant association of provider type
with systolic BP or odds of blood pressure control below a
threshold of 140 mmHg systolic and 90 mmHg diastolic BP, but
did find that diastolic BP was 3.29 mmHg greater in patients
treated by the public versus private sector (p = 0.042) [44]. The
two other studies evaluating public versus private provision had a
high risk of confounding, one of which was set in Greece and one
in the US. The study set in Greece found increased rates of
medication adherence in patients treated by a private physician
compared to those treated in the National Health System
(medication adherence with private physician 25.1% versus
10% of those with a physician in rural areas and 8.8% of with
a physician from the National Health System, p,0.005 for
between group differences) [74]. The study set in the US did not
provide strong evidence of improved HT control in patients cared
for by private providers (unadjusted OR for HT control for
private versus non-private provider 1.20, 95% CI 0.62–2.32) [75].
Interventions Involving More Than One Health System
Building Block
Four studies were included that evaluated outcomes associated
with complex regional or national health policy interventions, which
incorporated components from more than one health system
domain (Table 7). Two of these studies were conducted in high-
income countries, one in Finland and one in Trinidad and Tobago,
one was conducted in a higher-middle-income country, Iran, and one
was conducted in a lower middle-income country, Cameroon
[28,31,38,39]. None of the four studies had a low risk of bias. All
four studies showed improvements in HT outcomes after the
delivery of the intervention, although for one study there is a high
probability that this could be due to random sampling error [38].
Table 2. Summary of findings of studies examining the associations of arrangements relating to human or physical resources with
hypertension outcomes.
Health System
Arrangement Study Setting and Sample Size
Study
Design
Findings (95% CIs Given in Brackets Where Available).
ORs Are Adjusted for Confounding Unless Stated
Otherwise.
Risk of Bias
Assessment
Physical
resources
Distance to health
facility
Ambaw et al.
2012 [47]
Ethiopia - University hospital,
mixed rural and urban
population
n= 384
Cross-
sectional
OR for medication adherence travel time to health facilities
,30 min versus .30 min 2.02 (1.19–3.43)
Low risk of bias.
Human resources
Grade of treating
physician
Federman et al.
2005 [48]
US - All male Veterans Affairs
population
n= 15,893
Cross-
sectional
OR for BP control (baseline = 1 for resident). Mid level
doctor 1.12 (0.98–1.28), attending 1.23 (1.08–1.39)
Unclear risk of non-
differential
misclassification.
Physician
specialism
Mejia-Rodriguez
et al. 2009 [43]
Mexico - Regional Family
medicine units
n= 4,040
Cross-
sectional
OR for uncontrolled HT in those treated by non-specialists
versus specialists 1.43 (1.20–1.71)
Unclear risk of non-
differential
misclassification.
Per capita supply
of health
professionals
Bleich et al. 2007
[41]
Mexico - Nationally
representative sample
n= 2,130
Cross-
sectional
OR for HT treatment 1.04 (0.85 to 1.26) and control 0.81
(0.61–1.09) in areas with high versus low supply of health
professionals.
Unclear risk of non-
differential
misclassification.
doi:10.1371/journal.pmed.1001490.t002
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Table 3. Findings of quantitative studies examining the association of health insurance status with hypertension outcomes.
Study Setting and Sample Size
Study Design and
Length of Follow-up
Where Applicable
Findings (95% CIs Given in Brackets Where
Available). ORs Are Adjusted for Confounding
Unless Stated Otherwise.
Risk of Bias
Assessment
Fowler-Brown
et al. 2007
[49]
US. General population of four US
communities.
n= 15,972
Cohort (9-y follow-up) RR of being unaware of HT 1.12 (1.00–1.25) for uninsured
versus insured. RR for inadequate HT control 1.23 (1.08–1.39)
for uninsured versus insured.
Unclear risk of sample
bias.
Gai and Gu
2009 [26]
US. Nationally representative
sample
n= 3,679
Cohort (30-mo follow-
up)
OR of medication adherence: multiple insurance coverage
gaps 0.636 (0.418–0.969), uninsured 0.426 (0.282–0.757)
versus insured with no coverage gaps (baseline OR= 1)
Unclear risk of
differential
misclassification bias.
Ahluwalia
et al. 1997
[36]
US. Urban, low-income, African-
Americans
n= 221
Case-control OR of HT control: medical insurance versus no medical in-
surance 2.15 (1.02–4.52)
High risk of sample bias.
Unclear risk of non-
differential
misclassification bias.
DeVore et al.
2010 [37]
US. Diverse inner-city population
attending tertiary cardiology clinic
n= 154
Case-control OR of HT control for private versus public insurance = 3.40
(1.25–9.28)
Low risk of bias.
Shea et al.
1992a [35]
US. Hospital-based African
American and Hispanic inner-city
population
n= 207
Case-control OR for severe uncontrolled HT for uninsured versus insured
1.9 (0.8–4.6)
Unclear risk of non-
differential and
differential
misclassification bias.
Angell et al.
2008 [56]
US. Urban NYC population
n= 1,975
Cross-sectional Percentage aware of HT with private insurance (baseline) 86.5%
(80.3–90.9), Medicare 85.9% (72.8–93.2; p.0.05), other
government insurance 86.9% (77.3–92.8; p.0.05), uninsured
60.2% (46.0–72.8; p,0.05)
Percentage treated for HT with private insurance (baseline) 76.6%
(68.9–82.8), Medicare 81.2% (72.8–93.2; p.0.05), other govern-
ment insurance 74.5% (64.0–82.8; p.0.05), uninsured 42.6%
(28.7–57.7; p,0.05)
OR of HT control with Medicare 0.92 (0.36–2.33), other
government 0.72 (0.30–1.76), uninsured 0.89 (0.30–2.59)
versus private insurance (baseline OR= 1)
Low risk of bias and
confounding.
Bautista et al.
2008 [54]
US. Nationally representative
sample
n= 6,100
Cross-sectional OR of medication non-persistence (non-adherence) with no
health insurance 1.88 (1.24–2.83) versus health insurance
Unclear risk of non-
differential
misclassification bias.
Benkert et al.
2001 [76]
US. Urban Midwest population at
nurse-managed center.
n= 52
Cross-sectional Mean BP of those uninsured lower than those uninsured
(p,0.05 for diastolic BP, p.0.05 systolic BP).
High risk of sample bias.
Unclear risk of non-
differential
misclassification bias.
High risk of
confounding.
Bleich et al.
2007 [41]
Mexico. Nationally representative
sample
n= 2,130
Cross-sectional OR for HT control with seguro popular (insured) versus
uninsured, for treatment 1.50 (1.27–1.78), and for control
1.35 (1.00–1.82)
Unclear risk of non-
differential
misclassification bias.
Brooks et al.
2010 [50]
US. Framingham cohort
n= 1,384
Cross-sectional Men and women treated less when uninsured (OR 0.19
[0.07–0.56] and 0.31 [0.12–0.79], respectively). Men less
controlled when uninsured (OR 0.17 [0.04–0.68]), not women.
Low risk of bias.
Duru et al.
2007 [51]
US. Nationally representative
sample
n= 3,496
Cross-sectional OR for HT control (ref 1.0 for private insurance), Medicare =
0.80 (0.61–1.05), Medicaid 0.75 (0.47–1.20), no insurance 0.63
(0.44–0.92).
Low risk of bias.
Ford et al.
1998 [63]
US. Nationally representative
sample
n= 1,724
Cross-sectional Found no differences in HT awareness, treatment, or control
with no health insurance, Medicaid only, or other health
insurance compared to those insured fully.
High risk of non-
differential
misclassification bias.
He et al.
2002 [53]
US. General population
n= 4,144
Cross-sectional OR of HT control with government insurance = 1.08 (0.70–
1.68); private insurance = 1.59 (1.02–2.49), versus no insurance.
Low risk of bias.
Hill et al.
2002 [57]
US. Inner-city African American
men presenting to the emergency
department
n= 309
Cross-sectional No significant association between health insurance status
and HT control.
Unclear risk of sample
bias.
Hyman and
Pavlik 2001
[58]
US. Nationally representative
sample
n= 10,576
Cross-sectional OR for uncontrolled HT with insurance versus without 1.30
(0.79–2.13)
Low risk of bias.
Kang et al.
2006 [59]
US. Low SES Korean-American
elderly
n= 146
Cross-sectional OR of HT treatment with any insurance 2.41 (0.91–6.39),
Medicare 2.06 (0.66–6.42), Medicaid 3.21 (0.89–11.61), private
insurance1.46 (0.29–7.39) versus none. No association
between insurance type and control.
High risk of sample bias.
Unclear risk of non-
differential
misclassification bias.
High risk of confounding
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Considerations of Context
Seventeen of 53 included studies gave no information about
the socio-demographic, political, or economic context in which
the study was conducted [24,26,30–32,39,42,47,54,55,58,63,67,
69,70,74,75]. Of the 33 studies that provided contextual
information, this varied from single phrases or sentences to more
detailed contextual information (Box 2). 28 of 53 included studies
gave no description of the national or regional health system
where the study was conducted [22,26,31–34,37–39,43,46,53–
56,58–62,66–68,72,74–76]. Where a description of the health
system was given it was in most cases limited to a brief sentence
on insurance coverage or financing arrangements. A minority of
studies, usually those carried out in low-income countries, gave
more comprehensive descriptions of some aspects of the health
system (Box 2).
Considerations of Health Systems Complexity
Eleven of the 53 studies discussed linkages or interdependencies
between health system domains [24,28,35,36,41,57–59,63,69,70].
Eight of these 11 studies discussed the importance of the
interdependence between health system financing and structures
relating to the delivery of care, with many emphasizing the link
between low levels of health insurance coverage in certain US
settings and a lack of structures providing access to regular high
quality medical care [24,35,36,58,59,63,69,70]. One study
described the link between wider social factors and factors relating
to health system financing in creating a barrier to care for African
American men in the US: ‘‘unemployment and lack of health
insurance are highly intercorrelated and constitute apparently
insurmountable barriers to traditional medical care for HBP.’’
[57]. One study, set in Mexico, discussed the positive interaction
between the presence of health insurance (financing) and the
supply of health professionals (human resources) in improving HT
outcomes [41].
Twenty-three of 53 studies considered how HT outcomes
may be influenced by relationships between health systems
factors and contextual factors, such as socioeconomic status, as
well as individual factors, such as gender, age, or co-morbidities
[22–24,31,36,41,47,50,54–57,59,63,66,70–72]. Five of these 23
studies used an established framework, such as the Anderson-
Aday model [36,55], or the Precede-PROCEED model to
describe the multiple factors, including health system factors,
that might determine HT outcomes at the individual level
[44,57,59].
Discussion
Despite the limited scope and variable quality of literature
found, as well as the context specificity of the findings, it remains
possible to make inferences about the effect of some health system
Table 3. Cont.
Study Setting and Sample Size
Study Design and
Length of Follow-up
Where Applicable
Findings (95% CIs Given in Brackets Where
Available). ORs Are Adjusted for Confounding
Unless Stated Otherwise.
Risk of Bias
Assessment
Moy et al.
1995 [55]
US. Nationally representative
sample
n= 6,158
Cross-sectional OR of non-treatment of HT with Medicare or Medicaid versus
private 1.19 (0.99–1.41), Uninsured versus private 1.49
(1.18–1.89)
High risk of non-
differential
misclassification bias.
Unclear risk of
differential
misclassification bias.
Nguyen et al.
2011 [71]
US. Population sample from NYC
n= 1,334
Cross-sectional Public versus private insurance. OR for HT awareness 1.2
(0.4–4.1), treatment 1.1 (0.4–3.6). Average SBP lower with
private insurance versus public.
Low risk of bias.
Shea et al.
1992b [60]
US. Hospital-based African
American and Hispanic inner-
city population
n= 207
Cross-sectional Health insurance was not significantly associated with
medication adherence in a multivariable model.
High risk of sample bias.
Unclear risk of non-
differential
misclassification bias.
Turner et al.
2009 [62]
US. Mostly African American
women in Philadelphia
n= 300
Cross-sectional OR: In the past year had to go without usual BP medications
because not covered (yes) 1.29 (0.26–9.49) versus no
High risk of sample bias.
Wyatt et al.
2008 [61]
US. African American population
from Jackson, MS
n= 4,986
Cross-sectional No association reported between health insurance status
and HT awareness, treatment, or control.
Unclear risk of sample
bias.
RR, risk ratio; SES, socioeconomic status.
doi:10.1371/journal.pmed.1001490.t003
Box 2. Examples of Contextual Information and
Descriptions of the Health System from Included
Studies
[set in a] ‘‘contemporary multi-ethnic urban community’’
[72], or ‘‘developing country setting’’ [38]
‘‘Among industrialized countries, only the United States
lacks universal healthcare.’’ [63]
‘‘These cities have mixed Arab-Jewish populations and are
among the poorest in Israel, defined by the Israeli Social
Security Agency as having an SES in the lowest 10% of the
population.’’ [25]
[On a regional health system in Cameroon] ‘‘When the
program for hypertension and diabetes started in 2007,
there were 79 peripheral clinics in the area offering nurse-
led primary health care. Four of these had a physician
among the staff; the remaining 75 were exclusively led by
Non Physician Clinicians. Most (78%) of the peripheral
clinics were public where consultations are usually free of
charge but diagnostics and drugs for curative services
have to be paid out-of-pocket. The area also has eight
district hospitals and two missionary hospitals.’’ [28]
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Table 4. Findings of quantitative studies examining the association of medication or medical care costs or co-payments with
hypertension outcomes.
Study Setting and Sample Size Study Design
Findings (95% CIs Given in Brackets
Where Available). ORs Are Adjusted for
Confounding Unless Stated Otherwise. Risk of Bias Assessment
Medication costs
and co-payments
Briesacher et al.
2009 [34]
US. Nationally representative
sample of adults in employ-
ment.
n= 125,397
Cohort (12-mo
follow-up)
OR for medication adherence versus baseline
of 1 for US$0 co-payments. OR = 0.72 (p,0.05)
for US$1–US$9 co-payments, OR = 1.02 (p.0.05)
for US$10–US$29 co-payments, OR = 1.32
(p,0.05) for co-payments .US$30
Unclear risk of sampling bias
Elhayany and Vinker
2001 [25]
Israel. Mixed Arab/Jewish
patients from Ramle and
Lod (deprived populations)
n= 260
Cohort - before and
after study of
intervention. (2-y
follow-up)
Systolic BP and diastolic BP reduced by 8 and
3.2 mmHg, respectively, 24 mo following
intervention to eliminate prescription co-
payments (p,0.001).
High risk of selection bias. High risk
of confounding.
Hsu et al. 2006 [27] US. Sample from Kaiser
Permanente HMO in Northern
California
n= 104,948
Cohort (12-mo
follow-up)
OR for poor HT control = 1.05 (1.00–1.09) in
capped versus uncapped drug benefits
Low risk of bias.
Li et al. 2012 [29] US. Nationally representative
sample. Looking at effect of
the Medicare Part D medication
coverage gap on medication
adherence
n= 54,594
Cohort (Length of
follow-up unclear)
In 2006 Medicare Part D had a gap in coverage
for prescription payments, where recipients had
to cover 100% of drug costs above a threshold
of US$2250 per annum. Some insurance plans
covered this gap in coverage. ORs for non-
adherence versus a control group of people
entitled to complete low income medication
subsidy were as follows: brand name and generic
gap coverage 1.00 (0.88–1.15), generic only gap
coverage 1.50 (1.30–1.73), no gap coverage 1.60
(1.50–1.71).
Unclear risk of selection bias and
non-differential misclassification
bias.
Maciejewski et al.
2010 [30]
US. Veterans Affairs Medical
Centers
n= 7,090
Cohort (34-mo
follow-up)
2 y after co-payment increase: difference in
adherence =23.2% (23.1 to 23.3) in co-payers
compared to exempt controls.
Low risk of bias.
Pesa et al. 2012 [32] US. Nationally representative
sample
n= 26,688
Cohort (12-mo
follow-up)
For every US$1.00 increase in cost sharing, PDC
decreased by 1.1 d (p,0.0001)
Unclear risk of non-differential
misclassification bias.
Schoen et al. 2001
[65]
US. Uninsured patients at an
inner-city university-based
outpatient clinic
n= 137
Cohort (2-y follow-
up)
Percent people with uncontrolled HT reaching
therapeutic goal increased from 19.0% at base-
line to 36.8% at 6 mo (p,0.001) and 65.8% at 24
mo (p,0.01) after intervention to increase access
to free medications.
High risk of selection bias. Unclear
risk of non-differential
misclassification bias. High risk of
confounding.
Ahluwalia et al. 1997
[36]
US. Low-income, African-
Americans in an urban
ambulatory hospital
n= 221
Case-control OR of HT control when cost not a deterrent to
purchasing medications) versus cost is a
deterrent 3.63 (1.59–8.28)
Unclear risk of differential
misclassification bias.
Gandelman et al.
2004 [68]
US. General sample of Uni-
versity Medical Center patients
Westchester, NY
n= 614
Cross-sectional 38% of self-pay or Medicare patients (co-payers)
have controlled BP versus 70% of
Medicaid/privately insured (no co-payments)
p,0.001.
High risk of confounding.
Jokisalo et al. 2002
[67]
Finland. Nationally repre-
sentative sample
n= 1,561
Cross-sectional Medication adherence increases with presence
of special reimbursement payments for medi-
cation costs (p,0.001 between groups)
High risk of selection bias and
confounding. Unclear risk of non-
differential misclassification bias.
Mbouemboue et al.
2012 [46]
Cameroon. Mixed rural and
urban sample in Adamawa
Region
n= 117
Cross-sectional OR for HT awareness (baseline 1 for low cost of
medications): medium cost 0.35 (0.06–2.07), high
cost 0.44 (0.07–2.75)
Unclear risk of non-differential
misclassification bias.
de Santa-Helena
et al. 2010 [42]
Brazil. Patients from family
health units in Blumenau
n= 595
Cross-sectional OR for non-adherence: Those who pay for
medications versus those who have drugs
provided by SUS (health service) = 4.9 (1.6–15.3)
Unclear risk of non-differential
misclassification bias.
Yoon and Etner
2009 [66]
US. Generally representative
US sample, all insured.
n= 83,893
Cross-sectional Amongst people with low to median baseline
levels of adherence to medication (10th, 25th,
and 50th centile) increased co-payments, at all
levels, had a significant negative effect on
adherence to antihypertensive medication. (see
Table S1 for detail).
Unclear risk of confounding.
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arrangements on HT outcomes. This is particularly the case for
the characteristics of the US health system, which while unique
among high income countries has features that can be found in
other parts of the world. Evidence from longitudinal studies
reported here suggests a small positive impact of the presence of
health insurance in the US on HT awareness and control, and
adherence to antihypertensive medication [26,49]. This is
supported by most, but not all case-control and cross-sectional
studies [36,41,50–56]. However, these findings can be considered
in relation to analogous studies, such as a 2008 systematic review
of longitudinal studies that was confined to those in the US, which
found improved long-term health outcomes, including reduced
mortality, in insured patients compared to uninsured patients [77].
We also found an association, in both longitudinal and cross-
sectional studies, between reduced co-payments or costs for
medications or medical care and improved HT control or
treatment adherence in multiple studies in US settings
[24,27,29,30,32,34,36,65,66,68], although in one of these studies,
by Briesacher et al., the relationship between reduced co-payments
and treatment adherence was only found for low levels of
medication co-payments, while the highest levels of co-payments
(.US$30) were, surprisingly, associated with improved medication
adherence. The study authors do not provide an explanation for
this result in the paper, but it could be that the subgroup of
patients with co-payments of US$30 or more for medications have
shared characteristics that were not analyzed in this study, such as
high socioeconomic status, which may confound the association
between co-payment levels and medication adherence. The
association between reduced medication co-payments and im-
proved HT outcomes was replicated in single studies from China,
Finland, Israel and Brazil [25,42,45,67] but not in a study of Hong
Kong Chinese, which found that fee payers had improved
medication adherence compared to those with fee waivers [33].
The finding of an association between reduced medication co-
payments and improved HT outcomes is intuitive and suggests
that costs of medications or health care consultations may act as a
barrier to optimal HT care in the US, and potentially other
settings, including LMICs. A relationship between increased
medication co-payments and treatment discontinuation has also
been reported for diabetes care in the US [78].
Although lacking longitudinal studies, we found a large positive
association between having a routine physician or place of care for
HT management and treatment, awareness, control, and adher-
ence to antihypertensive treatment, again in the US
[35,36,53,55,56,60,70–73]. This finding is consistent with a recent
systematic review of the effect of a usual source of care, showing an
association with improved preventive services and chronic disease
control [79]. Although it is unclear whether having a routine
physician or a place for HT care is more important, this may
matter less than the implication that the absence of a consistent
source of care reduces awareness, treatment, and control of HT. It
is possible, however, that this effect is linked to health system
financing arrangements, as those without insurance or facing high
co-payments may be least likely to have consistent access to care
[70]. There were no longitudinal studies looking at differences in
outcomes of HT management provided by the private or public
sector, and the four cross-sectional studies considering this
question were all at risk of bias, were in different settings, and
had different findings, so general inferences were not possible
[42,44,75,80].
All four included studies that evaluated complex multi-compo-
nent national or regional policy interventions reported some
improvement in HT care. These studies had significant method-
ological flaws including, in some cases, a lack of an adequate control
group, precluding attribution of the improvement in HT outcomes
to the intervention. However, despite their limitations, these studies
Table 4. Cont.
Study Setting and Sample Size Study Design
Findings (95% CIs Given in Brackets
Where Available). ORs Are Adjusted for
Confounding Unless Stated Otherwise. Risk of Bias Assessment
Yu et al. 2013 [45] China. Low income rural
residents in Shandong
province.
n= 204
Cross-sectional with
matched control
group
0% of intervention group (free-medication)
untreated for HT compared to 14.7% in control
(pay for medication) group (p,0.001)
Significantly improved adherence to
medication in intervention group compared to
control group (p= 0.034)
12.7% in intervention group versus 11.8%
in control group have controlled HT. P= 0.831
High risk of confounding
Unclear risk of non-differential
misclassification bias.
Co-payments for
medical care
Keeler et al. 1985
[24]
US. Nationally representative
sample, subset of RAND study
3,958
RCT (3–5-y follow-
up)
Mean difference in diastolic BP
(free plan - cost sharing plans) =21.9 mmHg
(23.5 to 20.3) p,0.05.
Mean difference in systolic BP hypertensive
patients =21.8 mmHg (24.5 to 0.6) p.0.05.
High risk of participant and
personnel blinding. Unclear risk of
random sequence generation,
allocation concealment, and
blinding of outcome assessment.
Low risk of selective reporting and
incomplete outcome data.
Wong et al. 2010
[33]
Hong Kong. Chinese patients
in primary care
n= 83,884
Cohort (unclear
length of
follow-up)
OR for medication adherence
fee payers versus fee waivers
1.14 (1.09–1.19)
Low risk of bias.
Ahluwalia et al.
1997 [36]
US. Low-income, African-
Americans in an urban
ambulatory hospital
n= 733
Case-control OR of control when cost of care not a
deterrent versus cost as a deterrent 2.35
(1.19–4.67)
Unclear risk of differential
misclassification bias.
PDC, proportion of days covered by medication.
doi:10.1371/journal.pmed.1001490.t004
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may be useful for policymakers seeking to understand ways to
strengthen health systems for chronic disease care, particularly in
LMICs [6,15]. Labhardt et al., for example, demonstrated the
feasibility of task shifting from physicians to non-physician health
care workers for HT management in Cameroon, outlining the
integrated interventions across multiple health system domains
required to deliver improvements in health outcomes [28].
Research on health systems factors influencing HT care is
unequally distributed geographically. There is a lack of evidence
from LMICs, which bear around three-quarters of the global HT
burden [1]. Furthermore, even in high-income countries, health
systems barriers to care have been seen mainly as financial, while
the understanding of how a complex mix of other factors influence
care is relatively new. Intellectual and social resources, such as the
production and use of knowledge, social capital, and systems for
communication have only recently emerged as distinct areas of
research. As a result we found only a small number of studies
examining the impact of health system factors relating to human
resources or physical resources, and no studies evaluating the
impact of intellectual or social resources. This meant we were
unable to make firm conclusions about the effects of these factors
on HT outcomes.
A number of included studies used models to conceptualize the
mechanisms by which health systems factors may interact with
other key variables to influence HT outcomes. For example Moy
et al. and Ahluwalia et al. (1997) used the Anderson-Aday model,
which illustrates how three types of population characteristics can
influence medical care for HT [36,55]. Factors relating to health
systems such as the presence of a usual source of care or health
insurance are seen as ‘‘enabling’’ factors for medical care. These
‘‘enabling’’ factors interact with ‘‘predisposing’’ factors such as
ethnicity, gender, and socioeconomic status, and ‘‘need charac-
teristics’’ such as health status to determine access and outcomes of
medical care. Models such as Anderson-Aday are useful to the
extent that they can help demonstrate how health systems factors
may interact with other key factors in determining HT outcomes.
However, the studies reviewed here lack quantitative and
qualitative data on the nature and strength of these interactions,
highlighting an important gap to be addressed by future research.
Study Limitations and Strengths
The majority of included quantitative studies were cross-
sectional, and the few longitudinal studies we did find were restric-
ted to either health system arrangements relating to financing or to
evaluating the effects of complex multi-component interventions.
Inferences about temporal and potentially causal relationships
between health systems arrangements and HT outcomes, could,
therefore, only be made for a limited number of factors. In
addition, included quantitative studies were of variable method-
ological quality, with only one being randomized and a minority
having a low risk of bias for all assessed methodological domains.
When considering the findings of this review, the risk of
publication bias cannot be ruled out, particularly for the positive
findings relating to health insurance status, medication and
treatment costs and co-payments, and presence of a routine
setting of care, where it is possible that studies with null findings
are under-published. It was not possible to produce an Egger
funnel plot to formally assess the risk of publication bias, for the
same reasons that meta-analysis was not performed, namely the
heterogeneity in the study designs, outcome measures, analysis
strategies, and populations in the included studies. Reporting bias
within individual studies may also be a factor, many of which
might have explored the effects of multiple factors on HT
outcomes, and may have failed to report results for health system
arrangements which did not show significant effects. The lack of
published protocols for the included studies did not allow us to
estimate the magnitude of this potential bias. A strength of the
review is the addition of forward and backward searching methods
to the initial database search for articles. A number of additional
studies were identified using these methods, before reaching a
saturation point at which the only relevant studies being identified
were already included. We included only two qualitative studies,
which did not contribute important data about the views of
policymakers and health care workers on health systems factors
affecting HT care, contrary to what we had initially hoped.
The use of a conceptual health systems framework facilitated
the conduct of the review, enabling systematic generation of terms
for the search strategy and for classification of included studies
according to the domains in the conceptual framework. However,
the classification and reporting of our findings according to health
system domain does not encourage the integrated view of health
systems that the framework promotes. For example, classifying the
effect of usual source of care into the domain of health systems
governance and delivery obscures the fact that the delivery of care
from a regular source is very much dependent on human and
physical resources inputs to the health system. The difficulties in
presenting such complexities are perhaps a reflection of the fact
that few of the included studies explored inter-linkages between
health system components, with the majority exploring the
association between health system arrangements and HT
Table 5. Findings of quantitative studies examining the association of physician remuneration models with hypertension
outcomes.
Study
Setting and Sample
Size
Study Design and
Length of Follow-up
Where Applicable
Findings (95% CIs Given in Brackets
Where Available). ORs Are Adjusted For
Confounding Unless Stated Otherwise. Risk of Bias Assessment
Tu et al. 2009 [40] Canada. Primary care in
Ontario.
n=135
Ecological Differences in rates of HT awareness (p= 0.22),
treatment (p= 0.01) and control (p,0.01)
between capitation, salary, and fee for service
practices. Highest rates of awareness in salary
practices. Highest rates of treatment and
control in capitation practices.
Unclear risk of selection bias.
Udvarhelyi et al.
1991 [69]
US. Health care facilities
with both capitation and
fee-for service patients
n=246
Cross-sectional OR for HT control = 1.82 (1.02–3.27) for HMO
(capitation) versus fee-for-service patients.
Unclear risk of selection bias. Unclear
risk of misclassification bias.
doi:10.1371/journal.pmed.1001490.t005
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Table 6. Findings of studies examining health systems arrangements relating to health systems delivery and governance.
Study Setting and Sample Size Study Design
Findings (95% CIs Given in Brackets
Where Available)
ORs Are Adjusted for Confounding
Unless Stated Otherwise. Risk of Bias Assessment
Routine place of care for HT
Angell et al. 2008 [56] US. Urban population from
NYC
n= 1,975
Cross-sectional HT awareness with a routine place of care
85.1% versus 65.5% without (p,0.05). HT
treatment with routine place of care 76.4%
versus without 42.1% (p,0.05). OR for HT
control without a routine place of care 0.21
(0.07–0.66) versus with a routine place of care
Low risk of bias.
He et al. 2002 [53] US. General population
n= 4,144
Cross-sectional OR for control for same health facility of care
2.77 (1.88–4.09) versus lack of same facility of
care
Low risk of bias.
Hyman and Pavlik, 2001 [58] US. Nationally represen-
tative sample
n= 10,576
Cross-sectional OR for lack of awareness of HT: has usual
source of care: 1.12 (0.87–1.43) versus has no
usual source of care. OR for acknowledged
uncontrolled HT: has usual source of care:
1.07 (0.63–1.84) versus no usual source of care.
Low risk of bias.
Moy et al. 1995 [55] US. Nationally represen-
tative sample
n= 6,158
Cross-sectional OR for no HT treatment (reference 1 for
physician’s office) Clinic OR = 1.07 (0.90–1.28),
Emergency department OR= 1.36 (0.73–2.55),
No usual place of care OR= 3.94 (3.05–5.08)
High risk of non-differential
misclassification. Unclear risk of
differential misclassification.
Nguyen et al. 2011 [71] US. Population sample
from NYC
n= 1,334
Cross-sectional HT awareness: OR = 1.0 (0.2–5.6) no usual care
versus usual place of care (baseline). HT
treatment OR= 0.2 (0.1–0.8) no usual care
versus usual place of care (baseline). Systolic
BP 16.4 mmHg higher with no usual place of
care (p= 0.02).
Low risk of bias.
Spatz et al. 2010 [70] US. Nationally represen-
tative sample
n= 6,672
Cross-sectional APR for being untreated = 2.43 (1.88–2.85) for
no usual source of care versus having a usual
source of care.
Low risk of bias.
Routine physician for HT care
Shea et al. 1992a [35] US. Hospital-based African
American and Hispanic
inner-city population in NYC
n= 207
Case-control OR for severe uncontrolled HT with no
routine physician 3.5 (1.6–7.7) versus with a
routine physician
Unclear risk of differential and non-
differential misclassification.
Ahluwalia et al. 2010 [73] US. West Virginian women
in a screening initiative
n= 733
Cross-sectional OR of having uncontrolled HT with a regular
physician 0.34 (0.13–0.88) versus no regular
physician
High risk of sample bias. Unclear
risk of non-differential
misclassification bias.
He et al. 2002 [53] US. General population
n= 4,144
Cross-sectional OR for HT control same health provider of
care 2.29 (1.74–3.02) versus lack of same
provider of care
Low risk of bias.
Hill et al. 2002 [57] US. Inner-city African
American men presenting to
the emergency department
n= 309
Cross-sectional Non-significant association between regular
MD for HT care and HT control, magnitude
of association not reported in paper.
Unclear risk of sample bias.
Moy et al. 1995 [55] US. Nationally represen-
tative sample
n= 6,158
Cross-sectional OR for no treatment (reference 1 for general
or family practitioner), Internist OR = 0.82
(0.67–1.00), Non primary care physician
OR=1.20 (0.97–1.49), No particular physician
OR=2.61 (2.15–3.18)
High risk of non-differential
misclassification. Unclear risk of
differential misclassification.
Shea et al. 1992b [60] US. Hospital-based African
American and Hispanic
inner-city population
n= 207
Cross-sectional OR for non-adherence for lack of primary
care physician 2.9 (1.36–6.02 versus presence
of primary care physician.
High risk of sample bias. Unclear
risk of non-differential
misclassification bias.
Victor et al. 2008 [72] US. Mostly non-Hispanic
African Americans from
Dallas County
n= 1514
Cross-sectional OR for HT awareness 3.81 (2.86–5.07), treat-
ment 8.36 (5.95–11.74), and control 5.23 (3.30–
8.29): Has a regular physician versus has no
regular physician.
Low risk of bias.
Routine physician or place of
care for HT
Ahluwalia et al. 1997 [36] US. Low-income, African-
Americans in an urban
ambulatory hospital
n= 221
Case-control OR of HT control: Regular source of care 7.93
(3.86–16.29) versus no regular source of care.
Unclear risk of differential
misclassification.
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Table 6. Cont.
Study Setting and Sample Size Study Design
Findings (95% CIs Given in Brackets
Where Available)
ORs Are Adjusted for Confounding
Unless Stated Otherwise. Risk of Bias Assessment
Private versus public
provision of care
Dennison et al. 2007 [44] South Africa. Peri-urban
black South Africans
n= 403
Cross-sectional No significant effect of provider type on
systolic BP or odds of BP control below
threshold (.140 mmHg systolic and
.90 mmHg diastolic BP). Diastolic BP
3.29 mmHg greater in public versus private
sector (p=0.042).
Unclear risk of sample bias.
Kotchen et al. 1998 [75] US. Inner-city African
American population from
Milwaukee
n= 583
Cross-sectional Unadjusted OR for HT control: Private
provider 1.20 (0.62–2.32) versus non-private
provider
High risk of confounding. Unclear
risk of sample bias.
de Santa-Helena et al.
2010 [42]
Brazil. Patients from family
health units in Blumenau
n= 595
Cross-sectional OR for non-adherence: Treated by public
health service (SUS) 1.8 (1.1–2.7) versus
private medical provider.
Unclear risk of non-differential
misclassification.
Yiannakopoulou et al.
2005 [74]
Greece. Patients admitted
for elective surgery in Athens.
n= 1,000
Cross-sectional Medication adherence with private physician
25.1% versus 10% of those with physician in
rural areas and 8.8% of with physician from
the National Health System (p,0.005
between groups)
High risk of confounding. Unclear
risk of non-differential
misclassification.
APR, adjusted prevalence ratios.
doi:10.1371/journal.pmed.1001490.t006
Table 7. Description and summary of findings of studies evaluating complex national or regional interventions incorporating
components from more than one health system building block.
Study, Setting and
Sample Size Study Design Summary of Intervention
Health System
Building Blocks
Included Summary of Findings
Risk of Bias
Assessment
Nissinen et al. 1983
[31]
North Karelia –
Finland
n=3,002
Cohort study with
control area – 5-y
follow-up from
1972–1977
Introduction of systematic HT care within
the existing primary health care structure.
The program featured public health edu-
cation, training of health personnel,
reorganization of primary care services,
and creation of an information system.
1. Human resources
2. Physical resources
3. Delivery and
governance.
BP levels fell further in
both hypertensive men
and women in inter-
vention region compared
to control region (p,0.001)
High risk of selection bias
High risk of confounding.
Labhardt et al.
2010 [28]
Central Region,
Cameroon.
n=493
Cohort study –
before and after
intervention, no
control group.
Median follow up
102 d.
Integration of care for HT and type 2
diabetes into the existing primary health
care system by task shifting from physicians
in hospitals to non-physician clinicians in
health centers.
The intervention included training, equip-
ment and regional supervision and
monitoring. Local treatment protocols were
adapted from international guidance.
1. Human resources
2. Physical resources
3. Intellectual
resources
4. Delivery and
governance.
Fall in BP from baseline to
follow up: Systolic BP fell
by 226.5 mmHg (95% CI
212.5 to 240.5). Diastolic
BP fell by 17.2 mmHg (95%
CI 27.1 to 227.3)
High risk of selection
bias and differential
misclassification bias.
Khosravi et al. 2010
[38].
Iran, Intervention
areas Ifsahan and
Najaf-Abad
n=12,514/9,572
(pre-/post-
intervention survey)
Ecological study –
surveys performed
before and after
intervention. (6-y
follow-up)
Reference area
included.
Ifsahan Healthy Heart Program:
Complex regional intervention incor-
porating 3 strategies
1. Educating health professionals in HT
management (includes publication of local
guidelines).
2. Public education.
3. Occasional free BP measurement and
cardiovascular risk assessment services.
1. Human resources
2. Intellectual
resources
3. Delivery and
governance.
Improvement in BP
awareness, treatment and
control in intervention area
(p,0.001 for all outcomes).
Improvements also seen in
reference area. (p,0.05 for
all outcomes)
High risk of confounding.
Gulliford et al. 1999
[39].
Trinidad and
Tobago.
n=690/1,597 (pre-/
post intervention
survey)
Ecological study –
surveys performed
before and after
intervention. (5-y
follow-up)
National intervention to improve diabetes
care in Trinidad and Tobago. Intervention
included:
1. Evaluation of diabetes care and feed-
back of findings.
2. Training workshops for doctors.
3. Publication and dissemination of
guidelines.
1. Human resources
2. Intellectual
resources
3. Delivery and
governance.
Adjusted OR for BP
control amongst diabetics
post intervention versus
pre-intervention = 1.24
(95% CI 0.84–1.85)
High risk of selection
bias. High risk of non-
differential
misclassification.
doi:10.1371/journal.pmed.1001490.t007
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outcomes as simple linear relationships. There were some notable
exceptions, however; one study, for example, examined the
interaction of insurance status and the presence of a usual source
of care on HT outcomes [70].
Implications for Policy
We found an association between reduced co-payments for
health care, including for medications, and improved outcomes of
HT care in multiple US studies, and in single studies set in
Finland, Israel, and Brazil. This is consistent with a wealth of other
evidence on how co-payments reduce uptake of necessary care and
has clear implications for policy makers, particularly as the balance
of evidence does not suggest that reducing medication co-payments
leads to an increase in overall health care expenditure [81–84]. On
balance, we found health insurance coverage to be associated with
improved outcomes of HT care in US settings, suggesting that expan-
ded insurance coverage through The Patient Protection and Afforda-
ble Care Act (also known as Obamacare) may improve HT outcomes.
Implications for Research
This study indicates a number of possible implications for future
research. Ultimately, an increase in the number of high quality,
longitudinal and randomized studies identifying and analyzing the
effect of health system arrangements on HT care is required,
particularly in LMICs where the majority of the global burden of
HT lies, and where weaknesses in health systems are thought to
play a significant role in deficiencies in chronic disease care [6].
The focus on financing has highlighted important barriers to
effective care and control of HT but needs to be supplemented by
research examining other domains, such as delivery and gover-
nance mechanisms, production of knowledge, and the social
function in the health systems. Most existing studies have a focus
on independent effects of different health systems arrangements,
thereby creating a ‘‘laundry list’’ of isolated components. Recog-
nizing the shortcomings of this approach, it is important that
future studies attempt to capture the complexities and interactions
between health systems arrangements. In addition, future national
or regional health systems strengthening programs that aim to
improve care for chronic conditions such as HT should be robustly
evaluated, using longitudinal controlled study designs where possible.
Moving forward, there is a clear need for more robust designs of
studies in a much wider range of settings, especially in LMICs.
This will ideally include cluster RCTs and prospective longitudinal
studies with detailed data on individual and health system
characteristics, complemented by qualitative studies to see inside
what is often a health systems black box. Such studies also call for
consistency in health systems definitions and outcome measures. A
particular challenge will be to take account of the complexity of
health systems and all health system domains, as well as
interpreting studies by not simply as showing what works, but
what works in what circumstances [85]. This review should help
inform the design of such studies. In particular, the findings are
being combined with multi-method appraisals of health systems to
understand the barriers faced by patients with HT and their health
workers to design cluster randomized trials in several LMICs [86].
Importantly, given that there are many health systems frame-
works, this review has shown the practicality of using the one
chosen, a framework that is also being used in the multi-method
appraisals and that has been found useful in similar previous
studies using diabetes as a probe to analyze health systems [12,13].
Research such as this addresses a crucial gap in understanding of
how different models of health systems contribute to health.
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Editors’ Summary
Background. In 2008, one billion people, three-quarters of
whom were living in low- and middle-income countries, had
high blood pressure (hypertension). Worldwide, hyperten-
sion, which rarely has any symptoms, leads to about 7.5
million deaths annually from heart attacks, stroke, other
cardiovascular diseases, and kidney disease. Hypertension,
selected by the World Health Organization as the theme for
World Health Day 2013, is diagnosed by measuring blood
pressure, the force that blood circulating in the body exerts
on the inside of large blood vessels. Blood pressure is highest
when the heart is contracts to pump blood out (systolic
blood pressure) and lowest when the heart relaxes and refills
(diastolic blood pressure). Normal adult blood pressure is
defined as a systolic blood pressure of less than 120
millimeters of mercury (mmHg) and a diastolic blood
pressure of less than 80 mmHg (a blood pressure of less
than 120/80 mmHg). A blood pressure reading of more than
140/90 mmHg indicates hypertension. Many factors affect
blood pressure, but overweight people and individuals who
eat fatty or salty foods are at high risk of developing
hypertension.
Why Was This Study Done? Most individuals can achieve
good hypertension control, which reduces death and
disability from cardiovascular and kidney disease, by making
lifestyle changes (mild hypertension) and/or by taking
antihypertensive drugs. Yet, in both developed and devel-
oping countries, many people with hypertension are not
aware of their condition and are not adequately treated. As
with other chronic diseases, weaknesses in health care
systems probably contribute to the inadequate treatment of
hypertension. A health care system comprises all the
organizations, institutions, and resources whose primary
purpose is to improve health. Weaknesses in health care
systems can exist at the national, regional, district, commu-
nity, and household level. In this systematic review (a study
that uses predefined criteria to identify all the research on a
given topic), the researchers investigate how national and
regional health care system arrangements influence hyper-
tension awareness, treatment, and control. Actions that
might influence hypertension care at this level of health care
systems include providing treatment for hypertension at no
or reduced cost, the introduction of financial incentives to
healthcare practitioners for the diagnosis and treatment of
hypertension, and enhanced insurance coverage in countries
such as the US where people pay for health care through
insurance policies.
What Did the Researchers Do and Find? The researchers
identified 53 studies that analyzed whether regional or
national health care systems arrangements were associated
with patient awareness of hypertension, treatment of
hypertension, adherence to antihypertensive medication
treatment, and control of hypertension. The researchers
used an established conceptual framework for health care
systems and an approach called narrative synthesis to
analyze the results of these studies, most of which were
conducted in the US (36 studies) and other high-income
countries (eight studies). Nearly all the studies evaluated the
effects of health system financing on hypertension out-
comes, although several looked at the effects of delivery and
governance of health systems on these outcomes. The
researchers’ analysis revealed an association between
reduced medication co-payments (drug costs that are not
covered by health insurance and that are paid by patients in
countries without universal free healthcare) and improved
hypertension control and treatment adherence, mainly in US
settings. In addition, in US settings, health insurance
coverage was associated with improved hypertension
outcomes, as was having a routine physician or place of care.
What Do These Findings Mean? These findings suggest
that minimizing co-payments for health care and expansion
of health insurance coverage in countries without universal
free health care may improve the awareness, treatment, and
control of hypertension. Although these findings are based
mainly on US studies, they are likely to apply more generally
but, importantly, these findings indicate that additional,
high-quality studies are needed to unravel the impact of
health systems arrangements on the management of
hypertension. In particular, they reveal few studies in low-
and middle-income countries where most of the global
burden of hypertension lies and where weaknesses in health
systems often result in deficiencies in the care of chronic
diseases. Moreover, they highlight a need for studies that
evaluate how aspects of health care systems other than
financing (for example, delivery and governance mecha-
nisms) and interactions between health care system
arrangements affect hypertension outcomes. Without the
results of such studies, governments and national and
international organizations will not know the best ways to
deal effectively with the global public-health crisis posed by
hypertension.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001490.
N The US National Heart Lung and Blood Institute has patient
information about high blood pressure (in English and
Spanish)
N The American Heart Association provides information on
high blood pressure (in several languages) and personal
stories about dealing with high blood pressure
N The UK National Health Service (NHS) Choices website
provides detailed information for patients about
hypertension and a personal story about hypertension
N The World Health Organization provides information on
controlling blood pressure and on health systems (in
several languages); its ‘‘A Global Brief on Hypertension’’
was published on World Health Day 2013
N MedlinePlus provides links to further information about
high blood pressure (in English and Spanish)
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